Clinical Characteristics and Risk Factors Analysis for the Recurrence of Pelvic Endodermal Sinus Tumors

Yanglong Guo

Zhejiang Cancer Hospital

Xi Chen

Zhejiang Cancer Hospital

Qingqing Lin

Hangzhou First People's Hospital

Tao Zhu

Zhejiang Cancer Hospital

Ying-Li Zhang (✉ zhangyl@zjcc.org.cn)

Zhejiang Cancer Hospital

Research Article

Keywords: pelvic endodermal sinus tumor, yolk sac tumor, embryonal carcinoma, FIGO stage, residual tumor, platinum-based chemotherapy,

Posted Date: November 29th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1079415/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: This study investigated the clinicopathological characteristics and factors influencing the recurrence of pelvic endodermal sinus tumor.

Methods: Fifty-four cases were retrospectively analyzed from at the Zhejiang Cancer Hospital. Imaging and serological indicators were used to determine whether disease recurred, to evaluate progression-free survival, and to compare the influence of related factors on disease recurrence. SPSS 19.0 software was used for statistical analysis. Statistical significance was defined as $p < 0.05$.

Results: The median age at initial treatment was 21 years (range, 11–52 years). Six patients had extragonadal endodermal sinus tumor, and four had histological features of endodermal sinus tumor combined with embryonal carcinoma. Thirty-nine patients underwent fertility-preserving surgery, 18 patients had a childbearing history, and eight patients had residual tumor after initial treatment. Twenty-six patients had a tumor diameter of more than 15 cm, and 30 patients had a serum α -fetoprotein level greater than 10,000 ng/mL before initial management. The median follow-up time was 47.5 months (range, 14–212 months). During follow-up, 15 patients experience recurrence, with a recurrence rate of 27.8% and a 5-year PFS rate of 61.1%. In univariate analysis, the International Federation of Gynecology and Obstetrics stage (stage III-IV VS. I-II; HR= 10.054 $p < 0.001$), residual tumor (yes VS. no for the first surgery; HR=5.014 $p = 0.001$), histological features (endodermal sinus tumor combined with embryonal carcinoma VS. endodermal sinus tumor; HR=4.130 $p = 0.018$), and use of platinum-based chemotherapy (courses ≥ 3 VS. courses < 3 ; HR= 0.188 $p = 0.004$) were independent factors influencing recurrence; age, childbearing history, tumor site, tumor size, and serum α -fetoprotein level before initial management did not affect recurrence. In multivariate analysis, only stage was an independent risk factor for progression-free survival stage III-IV VS. I-II; HR=6.923 $p = 0.019$.

Conclusions: Stage is a prognostic factor for recurrence of pelvic endodermal sinus tumor. The first surgery should remove the tumor as completely as possible, and initial treatment should require a sufficient dose and full course of platinum-based chemotherapy, which may reduce the recurrence rate. Patients with endodermal sinus tumor and embryonal carcinoma may have increased susceptibility of recurrence.

1 Introduction

Endodermal sinus tumor (EST), also known as yolk sac tumor, is rare and highly malignant. It usually occurs in infants, adolescents, and women. The sites of occurrence can be divided into gonads (ovaries, testes) and non-gonads (sacroccocygeal, mediastinal, retroperitoneal, lung, oral cavity, pineal gland and vagina)[1-3]. According to literature reports, extragonadal germ cell tumors account for approximately 1%–5% of all germ cell tumors[4-6].

The pelvic endodermal sinus tumor (PEST) is defined as an EST that occurs in the pelvic cavity. Patients with PEST usually present with pelvic masses accompanied by abdominal pain, abdominal distension,

vaginal bleeding, and similar symptoms.

PESTs are sensitive to chemotherapy and had a high mortality rate until the development of effective chemotherapy drugs. Since the 1980s, the use of platinum-based chemotherapy has greatly improved the prognosis of this disease[7]. However, tumor recurrence still occurs frequently.

PESTs are extremely rare, and little information is known about their clinical features and treatment outcomes. Moreover, there is currently a lack of studies about PEST with large sample sizes, so there has been no accurate conclusion about the factors related to recurrence in patients with PEST. If we can determine the relevant factors that affect the clinical recurrence of PEST, treatment will vastly improve. By clarifying the appropriate treatments for PEST, we can more rationally use medical resources and avoid wasting unnecessary medical resources to treat these patients. The purpose of this study was to investigate the clinical features of PEST and the factors affecting the recurrence of PEST.

2 Methods

2.1 Data collection

We retrospectively reviewed the clinical data of patients with PEST from January 2000 to December 2019 in the Cancer Hospital of the University of Chinese Academy of Sciences. The following data were collected: age, childbearing history, residual tumor, histological features (EST with or without embryonal carcinoma [EC]), growth site of EST, fertility-preserving surgery, International Federation of Gynecology and Obstetrics (FIGO) stage, tumor size, courses of platinum-based chemotherapy, α -fetoprotein (AFP) level before the initial treatment, surgical approach and method, and recurrence.

2.2 Follow-up protocol

After treatment, the patients were observed every 2–4 months in the first 2 years, every half year in years 3–5, and every year after 5 years. The follow-up included assessment of the physical condition, physical examination, serum tumor markers, and imaging-related examinations. Patients were observed via outpatient visits or a telephone connection. The follow-up period continued until February 28, 2021, or the tumor recurrence date.

2.3 Evaluation indicator

After the initial treatment, data from the imaging examination and serological examination were collected as the baseline characteristics. Patient health was regularly reviewed by imaging and serological indexes. The imaging and serological indexes of each review were compared with the baseline data. Recurrence was defined as complete remission after initial treatment, increased tumor marker AFP, and/or imaging findings indicating tumor progression 1 month after discontinuation of treatment. The time points of recurrence were recorded. Progression-free survival (PFS) was defined as the interval between the initial treatment and tumor recurrence. If the patient was lost to follow-up, PFS was defined as the disease-free survival time at the last follow-up.

2.4 Statistical analysis

SPSS 19.0 software (International Business Machines Corporation, America) was used for statistical analysis. Univariate analysis was performed using the Kaplan-Meier method, and the differences were compared by log-rank tests. A multivariate Cox proportional regression model was used for multivariate linear regression analysis. $P < 0.05$ was regarded as statistically significant.

3 Results

The clinical characteristics of 54 patients with PEST are summarized in Table 1. The median age at initial treatment was 21 years (range, 11–52 years). Thirty-six patients (66.7%) had a childbearing history; the serum AFP level before initial management was $\geq 10,000$ ng/mL in 30 patients (55.6%); six patients had extra-gonadal EST; and the tumor size was ≥ 15 cm in 26 patients (48.1%).

All 54 patients underwent open surgery. Forty-two patients (77.8%) chose to preserve fertility. The surgical procedures performed were as follows: lymphadenectomy ($n=32$, 59.3%), omentectomy ($n=39$, 72.2%), and unilateral salpingo-oophorectomy (USO; $n=47$, 87.0%). In addition, five patients (9.3%) underwent bilateral salpingo-oophorectomy (BSO); two patients (3.7%) underwent cystectomy; and 46 patients (85.2%) had no residual tumor (Table 2).

Among the 42 patients with fertility preservation, USO ($n=40/42$, 95.2%) and simple adnexectomy ($n=2/42$, 4.8%) were performed. Thirty-one patients underwent omental resection, and 22 underwent lymphadenectomy.

Of the 12 patients who did not receive fertility-sparing surgery, five patients underwent total hysterectomy with BSO; six patients underwent radical hysterectomy with USO; one patient underwent subtotal hysterectomy with USO; and 10 patients underwent lymphadenectomy. Omentectomy was performed in eight patients.

According to the pathological and stage criteria, the numbers of patients by stage were 26 in stage I, three in stage II, 22 in stage III, and three in stage IV.

When it came to chemotherapy, the median course of postoperative platinum-containing chemotherapy was four courses (range, 0–7 courses) in 54 patients, of which two patients did not receive adjuvant therapy. Fifty-two patients received platinum (cisplatin or carboplatin) chemotherapy. Among them, 46 patients received bleomycin+etoposide+cisplatin (BEP) chemotherapy; three patients received BEP and etoposide+cisplatin (EP) chemotherapy; one patient received BEP with cisplatin intraperitoneal perfusion (IP) chemotherapy; one patient received paclitaxel+carboplatin chemotherapy; and one patient received vindesine+carboplatin+ifosfamide, vindesine+pirarubicin+cisplatin, and cisplatin IP chemotherapy at different times (Table 3).

Fifteen of 54 patients experienced recurrence and had an average recurrence time of 13.1 months. Of these 15, two patients had FIGO stage I, 10 patients had FIGO stage III, and three patients had FIGO stage

IV. Two patients who did not receive chemotherapy experienced recurrence after primary surgery, and one patient with recurrence had only received platinum-containing chemotherapy twice after the initial treatment. The histological features of three patients with recurrent PEST were EST with EC. Six patients with recurrence had residual tumor after the first surgery.

After univariate analysis, the significant risk factors for PFS in patients with PEST included the course of platinum-based chemotherapy, the FIGO stage, the histological features (EST combined with EC), and the presence of residual tumor ($P < 0.05$). Age, childbearing history, tumor site, fertility-preserving surgery, tumor size, and serum AFP level before initial management did not affect PFS ($P > 0.05$; Table 4, Figs. 1-4). Only FIGO stage was an independent risk factor for PFS after multivariate analysis (Table 5).

Table 1. Characteristics of 54 patients with PEST

Characteristic	Total N (%)
Age(years)	
Median	21 (11-52)
<18	14 (25.9%)
≥18	40 (74.1%)
Childbearing history	
No	36 (66.7%)
Yes	18 (33.3%)
Stage	
I	26 (48.1%)
II	3 (5.6%)
III	22 (40.7%)
IV	3(5.6%)
Tumor site	
Ovarian	48 (88.9%)
Extragonadal	6 (11.1%)
Tumor size (cm)	
<15	28 (51.9%)
≥15	26 (48.1%)
Histological features	
EST without EC	50 (92.6%)
EST+EC	4 (7.4%)
Course of platinum-based chemotherapy	
<3	6 (11.1%)
≥3	48 (88.9%)
Serum AFP level before initial management (ng/mL)	
≤10,000	24 (44.4%)
≥10,000	30 (55.6%)

Total	54
--------------	-----------

EST, endodermal sinus tumor; EC, embryonal carcinoma; AFP, α -fetoprotein.

Table 2. Summary of surgical information in 54 patients with PEST

Surgical information	Total N (%)
Surgical approach	
Laparotomy	54 (100.0%)
Minimally invasive surgery	0 (0.0%)
Omentectomy	
No	15 (27.8%)
Yes	39 (72.2%)
Lymphadenectomy	
No	22 (40.7%)
Yes	32 (59.3%)
Salpingo-oophorectomy	
No	2 (3.7%)
Unilateral	47 (87.0%)
Bilateral	5 (9.3%)
Fertility-sparing surgery	
No	12 (22.2%)
Yes	42 (77.8%)
Residual tumor	
No	46 (85.2%)
Yes	8 (14.8%)
Total	54

Table 3. Platinum-based chemotherapy of 54 patients with PEST

Chemotherapy regimen	Schema	Total N (%)
BEP		
Bleomycin (15 mg, days 1, 8, and 15)	Every 3 weeks for 1–7 cycles	46
Etoposide (100 mg/m ² , days 1–5)		
Cisplatin (20 mg/m ² , days 1–5)		
BEP+EP		
Bleomycin (15 mg, days 1, 8, and 15)	BEP every 3 weeks for 2–3 cycles;EP every 3 weeks for 1–3 cycles	3
Etoposide (100 mg/m ² , days 1–5)		
Cisplatin (20 mg/m ² , days 1–5)		
Etoposide (100 mg/m ² , days 1–5)		
Cisplatin (20 mg/m ² , days 1–5)		
TC		
Paclitaxel (100 mg/m ² , day 1)	Every 3 weeks for 4 cycles	1
Carboplatin (AUC=5, day 1)		
BEP+cisplatin (IP)	BEP for 1 cycle; cisplatin (IP) for 1 cycle	1
Bleomycin (15 mg, days 1, 8, and 15)		
Etoposide (100 mg/m ² , days 1–5)		
Cisplatin(20 mg/m ² , days 1–5)		

Cisplatin (IP) (60mg/m ² , day 1)	
VCI+VAP+cisplatin (IP)	
Vindesine (3mg/m ² , day 1)	VCI every 3 weeks for 4 cycles;VAP every 3 weeks for 2 cycles; cisplatin (IP) for 1 cycle 1
Carboplatin (AUC=5, day 1)	
Ifosfamide (1.5mg/m ² , day 1)	
Vindesine (3mg/m ² , day 1)	
Pirarubicin (30mg/m ² , day 1)	
Cisplatin (65 mg/m ² , day 1)	
Cisplatin (IP) (60mg/m ² , day 1)	

BEP, bleomycin+ etoposide+cisplatin; EP, etoposide+cisplatin; TC, paclitaxel+carboplatin;AUC, area under the curve; IP, intraperitoneal perfusion; VCI, vindesine+ carboplatin+ ifosfamide; VAP, vindesine+ pirarubicin+ cisplatin.

Table 4.Univariate analysis factor analysis for recurrence of PEST

Factors		PFS	
		P value	HR (95%CI)
Age	<18	0.555	0.715 (0.248–2.122)
	≥18		
Childbearing history	No	0.082	0.289 (0.065–1.280)
	Yes		
Histological features (EST+EC)	No	0.018	4.130 (1.156–14.761)
	Yes		
Extragenadal EST	No	0.637	1.429 (0.322–6.342)
	Yes		
Stage	I–II	<0.001	10.054 (2.253–44.859)
	III–IV		
Fertility-sparing surgery	No	0.316	2.106 (0.475–9.341)
	Yes		
Tumor size (cm)	<15	0.534	0.721 (0.256–2.028)
	≥15		
Residual tumor	No	0.001	5.014 (1.759–14.294)
	Yes		
Course of platinum-based Chemotherapy	<3	0.004	0.188 (0.052–0.677)
	≥3		
Serum AFP level before initial management (≥10,000ng/mL)	No	0.974	1.017 (0.368–2.814)
	Yes		

PFS, progression-free survival; HR, hazard ratio; EST, endodermal sinus tumor; EC, embryonal carcinoma; AFP, α-fetoprotein.

Table 5. Multivariate analysis factor analysis for recurrence of PEST

Factors		PFS	
		P value	HR (95%CI)
Course of platinum-based chemotherapy	<3	0.061	0.246 (0.057–1.068)
	≥3		
Stage	I–II	0.019	6.923 (1.368–35.031)
	III–IV		
Histological features (EST+EC)	No	0.220	2.327 (0.603–8.988)
	Yes		
Residual tumor	No	0.509	1.512 (0.443–5.166)
	Yes		

PFS, progression-free survival; HR, hazard ratio; EST, endodermal sinus tumor; EC, embryonal carcinoma.

4 Discussion

EST is the second most common ovarian germ cell malignancy[8] and is characterized by varied and diverse histological patterns[9]. Most ESTs synthesize AFP, so elevation of this tumor marker can support a diagnosis. Fifty percent of ESTs are mixed and contain other germ cell elements, including EC, teratoma, germinoma, and choriocarcinoma. In addition, Schiller-Duval body is a histopathological feature of EST[5].

Our study included a large sample size from a single center for the retrospective study of PEST. The study included 48 patients with ovarian EST and six with extra-ovarian EST—a rare representation in the existing literature.

With regard to risk factors for the EST recurrence, multiple researchers have attempted to determine accurate markers. Yang et al. [10–11] believed that the size of postoperative residual tumor affected the prognosis of ovarian EST. A smaller residual tumor reflected a better prognosis. Kawai et al. [12] reported that the 5-year survival rate of patients with residual tumors larger than 2 cm (36%) was significantly lower than that of patients with residual tumors smaller than 2 cm (82%; $P < 0.05$). Nawa et al. [13] and Wang et al. [14] also reported that patients with small residual tumors after initial surgery had better prognoses. However, Nasioudis et al. [15] found no significant correlation between residual tumor and prognosis. Cicin et al. [16] reviewed the surgical data of 32 patients with ovarian EST: 10 patients underwent hysterectomy and BSO, 18 patients underwent USO, two patients underwent BSO, and two patients underwent cystectomy. The results showed no significant difference in efficacy between fertility-preserving surgery and radical surgery [16]. Zhao et al. [17] retrospectively analyzed the data of 130

patients with malignant ovarian germ cell tumor. The results showed no significant difference in overall survival (OS) and disease-free survival between patients with bilateral ovarian germ cell tumor and patients with unilateral ovarian germ cell tumor after 5 years. Mahdi et al. [18] studied the clinical data of 1,529 patients with bilateral germ cell tumors, spanning 19 years, from a United States cancer center. The results showed no significant difference in 5-year OS and PFS between patients with bilateral and unilateral ovarian germ cell tumors[18]. Frazier et al. [19], Neeyalavira et al. [20], Chen et al. [21], and Zhang et al. [22]believe that stage is an important factor affecting the prognosis (i.e., earlier stages associated with better prognosis).

In the univariate analysis of our study, we found that residual tumor (hazard ratio [HR]=5.014,95% CI: 1.759–14.294, P=0.001) andstage (HR=10.054,95% CI: 2.253–44.859, P<0.001) were risk factors for recurrence of PEST. In addition, in multivariate analysis, we found that stage (HR=6.923, 95% CI: 1.368–35.031, P=0.019) was an independent risk factor for PFS, whereas tumor size and site and the use offertility-sparing surgeryhad no significant effect on the recurrence of PEST.

Interestingly, we found no significant difference in PFS between extragonadal and ovarian EST. This may be due to the following reasons: 1) ESTs at different locations are essentially ESTs, which do not change with location. 2) ESTs at different locations are still sensitive to chemotherapy.Also, extragonadal EST may be treated according to ovarian EST standards.

In the literature, Gershenson et al.[23]reported the treatment of patients who had ovarian EST with BVP(bleomycin+vincristine+cisplatin) chemotherapy. The efficacy of treatment in stage I and II was 95%, and efficacy in stages III and IV was 80% and 60%, respectively. The efficacy of this regimen for patients with recurrence was 40%. Chen et al. [21] noted that a reasonable platinum-containing chemotherapy regimen can benefit patients with ovarian EST. In addition, reports by Nawa et al. [13],Cicin et al. [16], and Mitchell et al. [24]also identified a statistically significant difference in 5-year survival rates between patients with malignant germ cell tumor treated with platinum and those not treated with platinum.

In this study, the course of platinum-containing chemotherapy was a related factor that affected the recurrence of PEST (HR=0.004, 95% CI: 0.052–0.677, P=0.004). This result might be due to the sensitivity of PEST to platinum-based chemotherapy; if so, a sufficient amount of platinum-based chemotherapy should be given after surgery.

Patients with pure ESThave shown better prognoses than patients with other pathological types[19]. Some studied have shown no significant difference in prognosis between pure ovarian EST and germ cell tumor with mixed EST components[16,25]. However, Chen et al. [21] and Zhang et al. [22] noted that the pathological type is not a factor that affects the prognosis of ovarian EST.

We found that patients in our study with EST+EC were more likely to experience relapse than patients with EST without EC were(HR=4.130, 95% CI: 1.156–14.761, P=0.018). This finding has been rarely reported in the domestic or international literature.

Our results might be related to the following reasons: First, the degree of malignancy of EST was much higher than that of other types of germ cell tumors, such as dysgerminoma. The biological behavior of tumors associated with PEST combined with EC might be more malignant. Thus, it would be easier for patients whose histological features were EST combined with EC to experience relapse. Second, the chemosensitivity of EC is worse than that of other types of germ cell tumors, which leads to a higher risk of recurrence. However, this study still lacked sufficient sample size, so additional research is needed to verify this conclusion.

Some studies have reported other factors related to ovarian EST. Wang et al. [14] and de la Motte Rouge et al. [26] reported that AFP level affected the recurrence of ovarian EST, whereas Elashry et al. [27] found that AFP did not affect the prognosis of ovarian EST. Solheim et al. [28] reported that the prognosis of patients older than age 50 years was significantly worse than that of patients who were younger than age 50 years. Bilici et al. [29] also considered age a factor influencing prognosis, but Neeyalavira et al. [20] and Chen et al. [21] did not agree.

In this study, we found that age, childbearing history, and serum AFP level before initial management ($\geq 10,000$ ng/mL) were not factors influencing the recurrence of PEST.

5 Conclusion

We found that stage is a prognostic factor for recurrence of PEST. The first surgery for PEST should remove the tumor as thoroughly as possible, and the initial treatment should include sufficient doses of platinum-based chemotherapy, which may reduce the recurrence rate. Patients with histological features of EST combined with EC may be more likely to experience relapse.

Some shortcomings to this study still exist. The incidence of PEST is relatively small, and the known cases are limited. To our knowledge, the number of patients with histological features of EST combined with EC is extremely scarce. Therefore, larger sample clinical studies are needed to confirm the conclusions of this study.

This study primarily explored the factors influencing tumor progression in patients with PEST. Stage was a prognostic factor for recurrence of PEST, and the recurrence rate increased with increasing stage. The first surgery for PEST should remove the tumor as completely as possible, and the initial treatment should require sufficient doses and a full course of platinum-based chemotherapy to reduce the recurrence rate. In practice, patients with histological features of EST combined with EC may have an increased susceptibility to recurrence. However, because of the low incidence of PEST and the limited number of known cases, the conclusions need additional validation with large sample studies.

Declarations

Acknowledgements

Not applicable

Authors' contributions

YLG, TZ, and YLZ conceived and designed the study. YLG, QQL, XC extracted and analyzed data. TZ and YLZ were the statisticians who confirmed the analysis of this study. YLG wrote the manuscript. XC and YLZ critically revised the manuscript. All authors reviewed and approved the final manuscript.

Funding

This study was supported by the Foundation of Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2020KY077)

and Key Research Projects of Traditional Chinese Medicine of Zhejiang Province (2021ZZ007).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Approval to review the patients' medical records and pathological reports was

obtained from the institutional review board of Zhejiang Cancer Hospital, Zhejiang, China. Written informed consent was obtained from all patients.

Consent for publication

Written informed consent was obtained from the patient for publication and accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

References

- [1] M. Elbaz, R.E. Qadiri, K. Fouraiji, H. Jalal, J. Elhoudzi. (2020). Yolk sac tumor of vagina: a rare cause of vaginal bleeding in adolescents-a case report, Pan Afr. Med. J. 37.
- [2] F.J. Garcia-Gomez, J.L. Villar-Rodriguez, C. Beato-Zambrano, P.A. de la Riva-Perez, M.C. Calvo-Moron. (2021). 18F-FDG PET/CT in pure testicular Yolk Sac Tumor in adult, Int Braz J Urol. 47: 202–204.

- [3] S. Simpson, M. Simoni, P. Hui, H.S. Taylor, N. Buza. (2020). Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin, *Int J Gynecol Pathol.* 39: 247–253.
- [4] A.C. Mayhew, H. Rytting, T.A. Olson, E. Smith, K.J. Childress. (2021). Vaginal Yolk Sac Tumor: A Case Series and Review of the Literature, *J Pediatr Adolesc Gynecol.* 34: 54-60
- [5] Raynald, H. Yang, X. Zhang, L. Ma'ruf, C. Li, T. Jiang. (2021). Primary intracranial pure endodermal sinus tumor: A retrospective series of 6 cases in a single center and a systematic review of overall survival, *Neurochirurgie.*
- [6] D. Tamura, D. Maeda, T. Sato, T. Sugawara, H. Shirasawa, D. Shimizu, N. Sato, A. Goto, Y. Terada. (2020). An extragonadal yolk sac tumor presumed to be of postmeiotic germ cell origin by genetic zygosity analysis via single nucleotide polymorphism array, *Genes Chromosom. Cancer.* 59: 209–213.
- [7] D.M. Gershenson. (2012). Treatment of ovarian cancer in young women, *Clin Obs. Gynecol.* 55: 65–74.
- [8] Y. Wang, J. Yang, M. Yu, D. Cao, Y. Zhang, X. Zong, K. Shen. (2018). Ovarian yolk sac tumor in postmenopausal females: A case series and a literature review, *Med.* 97 e11838.
- [9] S. Ravishankar, A. Malpica, P. Ramalingam, E.D. Euscher. (2017). Yolk Sac Tumor in Extragonadal Pelvic Sites: Still a Diagnostic Challenge, *Am J Surg Pathol.* 41: 1–11.
- [10] Z.J. Yang, Z.C. Liu, R.J. Wei, L. Li. (2016). An Analysis of Prognostic Factors in Patients with Ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery, *Gynecol Obs. Invest.* 81: 1–9.
- [11] Z.J. Yang, R.J. Wei, L. Li. (2012). Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery, *Zhonghua Fu Chan Ke Za Zhi.* 47: 898–904.
- [12] M. Kawai, T. Kano, Y. Furuhashi, K. Mizuno, N. Nakashima, S.E. Hattori, S. Kazeto, S. Iida, M. Ohta, Y. Arii, et al. (1991). Prognostic factors in yolk sac tumors of the ovary. A clinicopathologic analysis of 29 cases, *Cancer.* 67: 184–192.
- [13] A. Nawa, N. Obata, F. Kikkawa, M. Kawai, T. Nagasaka, S. Goto, K. Nishimori, N. Nakashima. (2001). Prognostic factors of patients with yolk sac tumors of the ovary, *Am J Obs. Gynecol.* 184: 1182–1188.
- [14] X. Wang, Z. Ma, Y. Li. (2016). Ovarian Yolk Sac Tumor: The Experience of a Regional Cancer Center, *Int J Gynecol Cancer.* 26: 884–891.
- [15] D. Nasioudis, E. Chapman-Davis, M.K. Frey, T.A. Caputo, K. Holcomb. (2017). Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base, *Gynecol Oncol.* 147: 296–301.

- [16] I. Cicin, P. Saip, N. Guney, Y. Eralp, I. Ayan, R. Kebudi, E. Topuz. (2009). Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors, *Eur J Obs. Gynecol Reprod Biol.* 146: 210–214.
- [17] T. Zhao, Y. Liu, H. Jiang, H. Zhang, Y. Lu. (2016). Management of bilateral malignant ovarian germ cell tumors: Experience of a single institute, *Mol Clin Oncol.* 5: 383–387.
- [18] H. Mahdi, S. Kumar, S. Seward, A. Semaan, R. Batchu, D. Lockhart, H. Tamimi, A.R. Munkarah. (2011). Prognostic impact of laterality in malignant ovarian germ cell tumors, *Int J Gynecol Cancer.* 21: 257–262.
- [19] A.L. Frazier, J.P. Hale, C. Rodriguez-Galindo, H. Dang, T. Olson, M.J. Murray, J.F. Amatruda, C. Thornton, G.S. Arul, D. Billmire, F. Shaikh, F. Pashankar, S. Stoneham, M. Krailo, J.C. Nicholson. (2015). Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States, *J Clin Oncol.* 33: 195–201.
- [20] V. Neeyalavira, P. Suprasert. (2014). Outcomes of malignant ovarian germ-cell tumors treated in Chiang Mai University Hospital over a nine year period, *Asian Pac J Cancer Prev.* 15: 4909–4913.
- [21] C.A. Chen, H. Lin, C.S. Weng, K.C. Wen, C.H. Lu, H.H. Chou, Y.F. Huang, C.Y. Kang, C.M. Ho, M.H. Yu, C.Y. Chou. (2014). Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study, *Eur J Cancer.* 50: 3161–3167.
- [22] R. Zhang, Y.C. Sun, G.Y. Zhang, L.Y. Wu, J. Zuo. (2012). Treatment of malignant ovarian germ cell tumors and preservation of fertility, *Eur J Gynaecol Oncol.* 33: 489–492.
- [23] D.M. Gershenson. (1994). Management of early ovarian cancer: germ cell and sex cord-stromal tumors, *Gynecol Oncol.* 55: S62-72.
- [24] P.L. Mitchell, N. Al-Nasiri, R. A'Hern, C. Fisher, A. Horwich, C.R. Pinkerton, J.H. Shepherd, C. Gallagher, M. Slevin, P. Harper, R. Osborne, J. Mansi, T. Oliver, M.E. Gore. (1999). Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases, *Cancer.* 85: 2232–2244.
- [25] T. Kojimahara, K. Nakahara, T. Takano, N. Yaegashi, H. Nishiyama, K. Fujimori, N. Sato, Y. Terada, T. Tase, Y. Yokoyama, H. Mizunuma, T. Shoji, T. Sugiyama, H. Kurachi. (2013). Yolk sac tumor of the ovary: a retrospective multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU), *Tohoku J Exp Med.* 230: 211–217.
- [26] T. de la Motte Rouge, P. Pautier, C. Genestie, A. Rey, S. Gouy, A. Leary, C. Haie-Meder, P. Kerbrat, S. Culine, K. Fizazi, C. Lhomme. (2016). Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors, *Gynecol Oncol.* 142: 452–457.
- [27] R. Elashry, R. Hemida, H. Goda, S. Abdel-Hadyel. (2013). Prognostic factors of germ cell and sex cord-stromal ovarian tumors in pediatric age: 5 years experience, *J Exp Ther Oncol.* 10: 181–187.

[28] O. Solheim, J. Kaern, C.G. Trope, E. Rokkones, A.A. Dahl, J.M. Nesland, S.D. Fossa. (2013). Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009), *Gynecol Oncol.* 131: 330–335.

[29] A. Bilici, M. Inanc, A. Ulas, T. Akman, M. Seker, N.A. Babacan, A. Inal, O. Bal, L. Koral, A. Sevinc, G. Tufan, E.T. Elkiran, B.B. Ustaalioglu, T. Yavuzsen, N. Alkis, M. Ozkan, M. Gumus. (2014). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology, *Asian Pac J Cancer Prev.* 14: 6493–6499.

Figures

Figure 1

Progression-free survival (PFS) according to course of platinum-based chemotherapy

Figure 2

Progression-free survival (PFS) according to International Federation of Gynecology and Obstetrics stage

Figure 3

Progression-free survival (PFS) according to histological features

Figure 4

Progression-free survival (PFS) according to residual tumor